Zanzalintinib (XL092)

Metastatic colorectal cancer

Manufacturer: Exelixis
Regulatory submission: NDA submitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Diagnosis

1 evidence topic · 2 sources

Guideline-recommended molecular assessment at metastatic diagnosis

Assessment	Quoted biomarker
Mismatch-repair testing	“MMR”
RAS mutation testing	“KRAS”
RAS mutation testing	“NRAS”
BRAF mutation testing	“BRAF”